Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) missed earnings with its latest yearly results, disappointing overly-optimistic forecasters. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at CN¥6.6b, statutory earnings missed forecasts by an incredible 64%, coming in at just CN¥0.47 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Following the latest results, Hangzhou Tigermed Consulting's 18 analysts are now forecasting revenues of CN¥7.17b in 2025. This would be a meaningful 8.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 314% to CN¥1.96. In the lead-up to this report, the analysts had been modelling revenues of CN¥8.22b and earnings per share (EPS) of CN¥2.05 in 2025. It looks like sentiment has fallen somewhat in the aftermath of these results, with a substantial drop in revenue estimates and a small dip in earnings per share numbers as well.

View our latest analysis for Hangzhou Tigermed Consulting

The analysts made no major changes to their price target of CN¥59.95, suggesting the downgrades are not expected to have a long-term impact on Hangzhou Tigermed Consulting's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Hangzhou Tigermed Consulting analyst has a price target of CN¥80.00 per share, while the most pessimistic values it at CN¥32.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Hangzhou Tigermed Consulting's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Hangzhou Tigermed Consulting's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 8.6% growth on an annualised basis. This is compared to a historical growth rate of 20% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 13% per year. Factoring in the forecast slowdown in growth, it seems obvious that Hangzhou Tigermed Consulting is also expected to grow slower than other industry participants.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Hangzhou Tigermed Consulting. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Hangzhou Tigermed Consulting. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Hangzhou Tigermed Consulting going out to 2027, and you can see them free on our platform here..

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Hangzhou Tigermed Consulting that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.